GBM antibodies (the Goodpasture antigen)


Suspicion of Goodpasture’s syndrome.


EELISA with the purified antigen alpha 3 chain from type IV collagen.

Accredited analysis – read more at the Quality page.


The result is given as arbitrary units per ml.


Antibodies against glomerular basalmembrane (anti-GBM) is a strong indicator for Goodpasture (GP) syndrome. Goodpasture syndrome is a serious monofasic condition that targets mainly kidneys in the form of a rapid progressive glomerulonephritis. Lung commitment with bleeding is also possible. The damages are mediated by GBM antibodies that are targeting the alpha3 chain in type IV collagen of the basal membranes of the glomeruli and lung capillaries. The clinical picture can vary in severity, but most patients have an acute phase with rapid glomerulonephritis. Early diagnosis and treatment is crucial to avoid irreversible tissue damages. The antibody levels can be used to monitor treatment effect.

If suspicion of Goodpasture syndrome remains despite a negative result, it is recommended to test anti-GBM of IgG4-subclass, which may occur without a positive result in the screening test. Contact the lab if further analysis is wished.

Read more about sampling

Packages and other tests

View other packages ANCA for Systemic Vasculitis/anti-GBM Goodpastures syndrome (501), Glomerulonephritis (500). View other tests ANCA IIF, ANCA – panel, dsDNA antibodies, MPO-ANCA (capture technique), MPO-ANCA (direct technique), Phospholipase A2 receptor (PLA2R) antibodies, PR3-ANCA (capture technique), PR3-ANCA (direct technique), Streptolysin O antibodies

Clinical studies